publication . Article . Other literature type . 2018

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.

Jean-Michel Nguyen; Soraya Saiagh; Marie-Christine Pandolfino; Amir Khammari; Lucie Peuvrel; Christophe Bedane; Anabelle Brocard; Mélanie Saint-Jean; Anne-Chantal Knol; Brigitte Dreno; ...
Open Access English
  • Published: 01 Mar 2018 Journal: Journal of Immunology Research (issn: 2314-8861, Copyright policy)
  • Publisher: Hindawi
  • Country: France
Abstract
<jats:p>Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regim...
Subjects
free text keywords: Article Subject, Immunology, Immunology and Allergy, General Medicine, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Immunologic diseases. Allergy, RC581-607, [SDV.CAN]Life Sciences [q-bio]/Cancer, Research Article, Melanoma, medicine.disease, medicine, Cell therapy, Regimen, Immunotherapy, medicine.medical_treatment, Tumor-infiltrating lymphocytes, Oncology, medicine.medical_specialty, Adverse effect, Internal medicine, business.industry, business, Therapeutic effect, Stage IIIC
Related Organizations
32 references, page 1 of 3

[1] A. Mackensen, G. Carcelain, S. Viel et al., “Direct evidence to support the immunosurveillance concept in a human regressive melanoma,” The Journal of Clinical Investigation, vol. 93, no. 4, pp. 1397-1402, 1994. [OpenAIRE]

[2] C. Jandus, D. Speiser, and P. Romero, “Recent advances and hurdles in melanoma immunotherapy,” Pigment Cell & Melanoma Research, vol. 22, no. 6, pp. 711-723, 2009.

[3] F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.

[4] C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517-2526, 2011.

[5] C. Robert, J. Schachter, G. V. Long et al., “Pembrolizumab versus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2521-2532, 2015.

[6] C. Robert, G. V. Long, B. Brady et al., “Nivolumab in previously untreated melanoma without BRAF mutation,” The New England Journal of Medicine, vol. 372, no. 4, pp. 320- 330, 2015.

[7] L. M. Muul, P. J. Spiess, E. P. Director, and S. A. Rosenberg, “Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma,” Journal of Immunology, vol. 138, pp. 989-995, 1987.

[8] S. A. Rosenberg and N. P. Restifo, “Adoptive cell transfer as personalized immunotherapy for human cancer,” Science, vol. 348, no. 6230, pp. 62-68, 2015. [OpenAIRE]

[9] M. J. Besser, R. Shapira-Frommer, A. J. Treves et al., “Clinical responses in a phase II study using adoptive transfer of shortterm cultured tumor infiltration lymphocytes in metastatic melanoma patients,” Clinical Cancer Research, vol. 16, no. 9, pp. 2646-2655, 2010.

[10] M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850-854, 2002.

[11] M. E. Dudley, C. A. Gross, R. P. Somerville et al., “Randomized selection design trial evaluating CD8+−enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma,” Journal of Clinical Oncology, vol. 31, no. 17, pp. 2152-2159, 2013.

[12] E. Ellebaek, T. Z. Iversen, N. Junker et al., “Adoptive cell therapy with autologous tumor infiltrating lymphocytes and lowdose Interleukin-2 in metastatic melanoma patients,” Journal of Translational Medicine, vol. 10, no. 1, p. 169, 2012.

[13] S. Pilon-Thomas, L. Kuhn, S. Ellwanger et al., “Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma,” Journal of Immunotherapy, vol. 35, no. 8, pp. 615-620, 2012.

[14] M. J. Besser, R. Shapira-Frommer, O. Itzhaki et al., “Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies,” Clinical Cancer Research, vol. 19, no. 17, pp. 4792-4800, 2013.

[15] B. Dréno, J. M. Nguyen, A. Khammari et al., “Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,” Cancer Immunology, Immunotherapy, vol. 51, no. 10, pp. 539-546, 2002.

32 references, page 1 of 3
Any information missing or wrong?Report an Issue